Search

Halozyme Therapeutics Inc

Cerrado

SectorSanidad

77.68 -0.74

Resumen

Variación precio

24h

Actual

Mínimo

76.91

Máximo

78.58

Métricas clave

By Trading Economics

Ingresos

292M

150M

Ventas

-75M

377M

P/B

Media del Sector

27.337

62.58

BPA

1.221

Margen de beneficios

39.832

Empleados

423

EBITDA

-62M

220M

Recomendaciones

By TipRanks

Recomendaciones

Comprar

Estimación a 12 Meses

+5.07% upside

Dividendos

By Acuity

Próximas Ganancias

4 ago 2026

Estadísticas de Mercado

By TradingEconomics

Capitalización Mercado

1.5B

9.1B

Apertura anterior

78.42

Cierre anterior

77.68

Noticias sobre sentimiento de mercado

By Acuity

27%

73%

62 / 340 Clasificación en Healthcare

Halozyme Therapeutics Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

21 jul 2026, 23:51 UTC

News

Regeneron Pharmaceuticals faces a class action lawsuit for securities fraud over misleading claims about Fianlimab-Libtayo trial results. Shares are lower in after-hours trading.

21 jul 2026, 23:51 UTC

News
Social Media

Pegasystems shares declined in after-market trading following second-quarter results that missed analyst expectations for earnings and revenue, amid concerns over future ACV growth.

21 jul 2026, 23:46 UTC

News

Adobe Inc. shares are declining in after-market trading following Morgan Stanley's downgrade to "underweight" and a reduced price target of $240.

21 jul 2026, 23:41 UTC

News

Raytheon Technologies secures a $49.7 million Navy contract for weapon system repairs, with shares trading higher in after-market hours.

21 jul 2026, 23:41 UTC

Social Media
News

Capital One Financial reported adjusted EPS of $5.81 and revenue of $15.85 billion, exceeding expectations, as shares rose in after-market trading.

21 jul 2026, 23:41 UTC

Macro News
ETF Constituents
News

Vanguard Information Technology ETF is little changed after market hours, despite broader market gains and negative contributions from Apple, Microsoft, and Nvidia.

21 jul 2026, 23:36 UTC

News
ETF Constituents

The Vanguard Growth ETF is trading roughly flat in after-market hours, reflecting minor fluctuations among its holdings, including declines from Apple, Microsoft, and Nvidia.

21 jul 2026, 23:36 UTC

Social Media
News

Micron Technology rose in after-market hours, supported by a semiconductor rally and a Bank of America upgrade to "buy" on strong AI demand.

21 jul 2026, 23:36 UTC

News

MongoDB shares traded higher after director Dwight Merriman sold 16,000 shares for $5.2 million under a pre-scheduled plan, retaining $496.55 million in holdings.

21 jul 2026, 23:32 UTC

News

United Community Banks Inc. shares rise in after-market trading after an upgrade to Buy, bolstered by Q2 2026 net interest income of $270.7 million.

21 jul 2026, 23:26 UTC

Correlated Moves
News

JPMorgan Chase & Co shares showed little change in after-market hours amid broader market movements. CEO Jamie Dimon raised concerns over geopolitical tensions and inflation.

21 jul 2026, 23:26 UTC

Social Media
Correlated Moves
News

Coinbase Global shares rose in after-market trading amid reports of a regulatory agreement that may benefit digital assets, with Bitcoin approaching $67,000.

21 jul 2026, 23:26 UTC

News

Lucid Group Inc. faces a class action lawsuit over alleged supplier quality issues, contributing to a decline in after-market trading. Shares earlier stabilized after a session low.

21 jul 2026, 23:26 UTC

News

Intuit Inc. shares are lower in after-market trading following a class action lawsuit alleging misleading statements about TurboTax revenue growth and competitive advantages.

21 jul 2026, 23:16 UTC

News

Sprinklr Inc reported first-quarter revenues of $219.5 million, exceeding expectations, but shares are lower in after-market hours amid sector concerns and mixed AI sentiments.

21 jul 2026, 23:16 UTC

News

Nasdaq shares rise in after-market hours following the dismissal of all claims in the Miami International litigation, positively impacting investor sentiment.

21 jul 2026, 23:16 UTC

News

Iridium Communications Inc. shares are higher in after-hours trading, reflecting positive market sentiment amid significant gains in technology and semiconductor stocks in Asia.

21 jul 2026, 23:16 UTC

News

Intel faces valuation scrutiny as modest growth expectations contrast with sector leaders benefiting from AI demand. Shares were roughly flat in after-market hours.

21 jul 2026, 23:11 UTC

News

Toast Inc shares are trading higher in after-market hours following the announcement of its second quarter 2026 financial results release on August 4.

21 jul 2026, 23:11 UTC

News

Pfizer Inc. options trading showed light volume, with calls outpacing puts and a put/call ratio of 0.56. Shares were little changed in after-market hours.

21 jul 2026, 23:06 UTC

News

General Motors plans a new generation of gasoline-powered Cadillac models, shifting from an all-electric strategy. Shares are higher in after-market trading.

21 jul 2026, 23:02 UTC

News

Park Aerospace shares lower in after-market hours following the unexpected death of Vice President Daniel McNamara, impacting investor sentiment and contributing to the decline.

21 jul 2026, 23:02 UTC

Event
News

Weatherford International shares advanced in after-market trading following second-quarter results, with revenues of $1.11 billion exceeding expectations despite a decline.

21 jul 2026, 23:02 UTC

News

Jefferies raised its price target on Genuine Parts Co to $130.00, contributing to after-market gains following a dip earlier in the session.

21 jul 2026, 23:02 UTC

Event
News
Social Media

AAR Corp shares are lower in after-market trading following mixed fourth-quarter results and cautious guidance, despite exceeding sales and EPS expectations.

21 jul 2026, 23:02 UTC

News

ServiceNow Inc. shares declined in after-market hours amid concerns about generative AI's impact on the enterprise software sector, according to Morgan Stanley.

21 jul 2026, 23:01 UTC

News
Social Media

Citigroup Inc declared a quarterly dividend of $0.67 per share, though shares are trading lower after-market amid ongoing market weakness.

21 jul 2026, 23:01 UTC

News

Norfolk Southern announced a quarterly dividend of $1.35 per share, contributing to shares trading higher in after-market hours following three lower sessions.

21 jul 2026, 23:01 UTC

News

DigitalOcean shares rise in after-market hours after Baird analyst initiates coverage with an Outperform rating. The stock closed at $119.09 in the prior session.

21 jul 2026, 23:01 UTC

News
Social Media

Chubb Ltd reported second-quarter net income of $2.85 billion, down from $2.97 billion a year earlier, contributing to lower after-market trading.

Comparación entre iguales

Cambio de precio

Halozyme Therapeutics Inc previsión

Precio Objetivo

By TipRanks

5.07% repunte

Estimación a 12 Meses

Media 81 USD  5.07%

Máximo 96 USD

Mínimo 57 USD

De acuerdo con 6 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Halozyme Therapeutics Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

6 ratings

3

Comprar

2

Mantener

1

Vender

Sentimiento

By Acuity

62 / 340 Clasificación en Sanidad

Noticias sobre sentimiento de mercado

Coyuntura alcista

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por encima de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Halozyme Therapeutics Inc

Halozyme Therapeutics, Inc., a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous (SC) fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; rilpivirine, cabotegravir, and N6LS BNAB for the treatment of HIV; ocrelizumab for multiple sclerosis; XYOSTED, an injection for SC administration of testosterone replacement therapy; and ATRS-1902, a proprietary drug device combination product. The company also provides Herceptin (trastuzumab), Herceptin Hylecta, and Phesgo to treat breast cancer; Mabthera SC for the treatment of chronic lymphocytic leukemia; HYQVIA to treat primary immunodeficiency disorders; and DARZALEX for patients with amyloidosis, smoldering myeloma, and multiple myeloma. In addition, it offers Epinephrine Injection to treat allergic reactions; nivolumab+relatlimab and ANTI-TIM3 for the treatment of solid tumors; ARGX-117 for multifocal motor neuropathy; atezolizumab; nivolumab; afgartigimod; teriparatide injections; and OTREXUP, a SC methotrexate injection for adults with severe active rheumatoid arthritis and severe recalcitrant psoriasis, as well as children with active polyarticular juvenile idiopathic arthritis. Further, the company provides ATRS-1902 for adrenal crisis rescue; ARGX-113; and ARGX-117 to treat severe autoimmune diseases in multifocal motor neuropathy. Halozyme Therapeutics, Inc. was founded in 1998 and is headquartered in San Diego, California.